Skip to content

Pulmonx Corporation LUNG Net Investment in Lease

Net Investment in Lease at other companies

Theravance Biopharma logo
Theravance BiopharmaTBPH
LQD
Liquidia CorporationLQDA
Viemed Healthcare, Inc. logo
Viemed Healthcare, Inc.VMD
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
LivaNova logo
LivaNovaLIVN
4D Molecular Therapeutics logo
4D Molecular TherapeuticsFDMT

Other financials

Income statement

See full
Revenue$20.6M-8.7%
Gross profit$16.0M-1.8%
Operating income-$13.0M+11.0%
Net income-$13.7M+5.5%
EPS (diluted)-$0.33+8.3%

Balance sheet

See full
Cash & equivalents$61.0M-2.4%
Total debt$56.3M-1.2%
Total equity$45.8M-41.1%
Total assets$120.0M-20.4%

Cash flow

See full
Operating cash flow-$10.1M+23.6%
CapEx$9.0K-97.0%
Free cash flow-$10.1M+25.3%

Valuation

See full
Market cap$54.91M-47.3%
Enterprise value$50.17M-43.5%
P/S0.6×-0.5×

Profitability

See full
Gross margin75.5%+2.0pp
Operating margin-58.8%-5.8pp
Net margin-60.1%-4.4pp
FCF margin-33.2%-4.4pp

Returns & leverage

See full
Return on equity-86.2%+62.6pp
Debt / equity1.2×+0.5×
Current ratio4.9×-0.1×

Where this comes from

Reported directly by Pulmonx Corporation in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Pulmonx Corporation’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pulmonx Corporation's net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pulmonx Corporation's net investment in lease?
Pulmonx Corporation (LUNG) reported net investment in lease of $17.65M in Q1 2026.
How has Pulmonx Corporation's net investment in lease changed year-over-year?
Pulmonx Corporation's net investment in lease decreased by 5.5% year-over-year, from $18.68M to $17.65M.
What is the long-term trend for Pulmonx Corporation's net investment in lease?
Over 5 years (2020 to 2025), Pulmonx Corporation's net investment in lease has grown at a 15.0% compound annual growth rate (CAGR), from $8.98M to $18.03M.